Ocugen, Inc. has priced $115 million of 6.75% convertible senior notes due 2034 in a private offering to qualified institutional buyers. The company expects to net about $99.5 million, or up to $112.6 million if the initial purchaser exercises an option to buy more. Ocugen plans to use approximately $32.7 million of the proceeds to repay an outstanding loan and related fees, with the remainder going to general corporate purposes. The notes bear interest semi-annually, mature in 2034, and have conversion features allowing holders to convert into Ocugen common stock starting in 2027, subject to conditions.
The global pharmaceutical surfactants market, valued at $4.5 billion in 2025, is projected to grow to $6.93 billion by 2035 at a CAGR of 4.42%. Growth is fueled by increasing use in drug formulation to enhance solubility, stability, and bioavailabili...
Noble Corporation reported weaker-than-expected revenue and earnings per share for Q2 2026 due to vessel suspensions and contract completions. Despite lowering its full-year 2026 guidance, the company maintains a strong backlog of $6.8 billion and ri...
Bitcoin fell more than 3% to around $63,494, hitting a 10-day low as tech stocks tied to AI plunged, notably South Korea's KOSPI dropping over 10%. This sell-off spread to digital assets, with Ethereum, Solana, and XRP also declining. Market uncertai...
CoinMarketCap's Altcoin Season Index increased to 53, indicating a slight improvement in altcoin performance relative to Bitcoin. However, this level remains below the 75 threshold that signals a full altcoin season, keeping the market in a neutral s...
Unilever reported its strongest quarterly volume growth in more than ten years, with underlying sales rising 5.8% in Q2, surpassing analyst expectations. Sales volumes increased 5.5%, and revenue reached €13.05 billion, beating forecasts. The company...
